AP Insights, News, Videos, and More

A new study released by the University of Central Florida finds that although most insurance plans cover the sublingual formulation of buprenorphine, significant barriers exist for the extended-release, injectable formulation.

Christopher M. Jones, PharmD, DrPH, MPH, CAPT US Public Health Service, will join the Substance Abuse and Mental Health Services Administration as director of the Center for Substance Abuse Prevention, effective August 21.

Results from an Ohio State University study suggest major progress in reducing youth vaping could be achieved with a complete restriction on sweet flavorings and cooling agents in both cartridge and disposable e-cigarette devices.

A drug designed to treat cannabis use disorder by selectively inhibiting the signaling pathway of the cannabinoid receptor has shown promise as a safe and effective treatment in a recent clinical trial.

The program will use HarmGuard FX testing strips, which are produced by Delaware-based SIVAD Diagnostic Medical Group.

Women who in recent years have turned 35, as well as women who have not had children by the age of 35, are the subgroups of females at the highest risk of engaging in binge drinking and having alcohol use disorder, according to a recent...

Xylazine, a veterinary sedative that is not approved for human use, has been found to potentially worsen the life-threatening effects of opioids, according to a study in rats that was released by the National Institutes of Health on Tuesday.

The discrepancy in overdose deaths between men and women identified in a NIDA-backed study could be attributed to a combination of biological, behavioral, and social factors.

Only 1 in 4 residential addiction treatment facilities caring for adolescents in the US offers buprenorphine, with just 1 in 8 offering buprenorphine for ongoing treatment, according to an Oregon Health & Science University study released on...